AnaptysBio, Inc

(NASDAQ:ANAB)

Latest On AnaptysBio, Inc (ANAB):

Date/Time Type Description Signal Details
2023-05-22 18:46 ESTNewsAnaptysBio upgraded to neutral at JP Morgan on clinical executionN/A
2023-05-21 00:00 ESTNewsStocks To Watch: Debt Ceiling Drama, Nvidia Earnings And Healthcare ConferencesN/A
2023-05-18 17:01 ESTNewsAnaptysBio initiated Outperform at TD Cowen on anti-inflammatory agentsN/A
2023-05-12 06:14 ESTNewsAnaptysBio GAAP EPS of -$1.58 misses by $0.53, revenue of $1.4M misses by $1.48MN/A
2023-04-25 14:45 ESTNewsGSK's Jemperli gets review in EU for expanded use in uterus cancerN/A
2023-03-31 01:05 ESTNewsAnaptysBio: Upside Could Be Lying Ahead Very NicelyN/A
2023-03-01 22:46 ESTNewsAnaptysBio GAAP EPS of -$0.93, revenue of $6.8MN/A
2023-01-13 19:42 ESTNewsAnaptysBio rises 10% on stock repurchase of up to $50MN/A
2022-11-09 02:12 ESTNewsAnaptysBio GAAP EPS of -$1.18 misses by $0.56, revenue of $1.29M misses by $12.14MN/A
2022-11-01 22:23 ESTNewsAnaptysBio raised to Buy at Guggenheim on prospects for checkpoint agonistsN/A
2022-10-05 18:17 ESTNewsAnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trialN/A
2022-09-14 00:51 ESTNewsAnaptysBio cut to Hold at Truist citing high bar for hair loss treatmentN/A
2022-09-12 13:42 ESTNewsAnaptysBio sells royalties from GSK-partnered Zejula for $45MN/A
2022-09-01 01:51 ESTNewsAnaptysBio skin condition candidate fails mid-stage trial; shares down 16%N/A
2022-08-08 18:55 ESTNewsAnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4MN/A
2022-05-04 22:42 ESTNewsAnaptysBio GAAP EPS of -$1.31 misses by $0.32, revenue of $0.97M misses by $4.08MN/A
2022-03-22 16:43 ESTNewsAnaptysBio names interim CEO as Hamza Suria steps downN/A
2022-03-22 16:42 ESTNewsAnaptysBio cut to neutral at Guggenheim on future of pipelineN/A
2022-03-14 23:38 ESTNewsAnaptysBio acne treatment imsidolimab fails in mid-stage trial; shares down 12%N/A
2021-11-05 01:02 ESTNewsAnaptysBio EPS beats by $0.64, beats on revenueN/A
2021-10-26 12:05 ESTNewsAnaptysBio climbs 14%, will monetize portion of JEMPERLI royalties for $250M with SagardN/A
2021-10-04 23:16 ESTNewsAnaptysBio reports updated data from imsidolimab mid-stage study in pustular psoriasisN/A
2021-08-18 04:46 ESTNewsAnaptysBio secures $20M milestone payment from GSK after JEMPERLI FDA approvalN/A
2021-08-18 04:46 ESTNewsANAB, TLRY, PFMT and BMRN among after hours moversN/A
2021-08-09 22:59 ESTNewsAnaptysBio EPS beats by $0.12, beats on revenueN/A
2021-07-20 18:44 ESTNewsAnaptysBio gains after report the company received a takeover offerN/A
2021-05-05 11:31 ESTNewsAnaptysBio EPS beats by $0.03, beats on revenueN/A
2021-04-24 05:15 ESTNewsAnaptysBio trades higher after FDA approval for Jemperli triggers $20M milestone paymentN/A
2021-04-24 05:14 ESTNewsGlaxoSmithKline wins EU approval for Jemperli in endometrial cancerN/A
2021-04-23 07:49 ESTNewsAnaptysBio is trading higher after FDA approval for Jemperli in endometrial cancer (updated)N/A
2021-03-17 12:05 ESTAnalyst RatingThe Analyst Target Price has increased from $26.75 to $28.5.Buy
2021-03-16 19:18 ESTNewsAnaptysBio is set for a catalyst-rich phase after the recent selloff: TruistN/A
2021-03-10 15:05 ESTAnalyst RatingThe Analyst Target Price has decreased from $30.75 to $26.75.Neutral
2021-03-09 03:06 ESTAnalyst RatingThe Analyst Target Price has decreased from $33.25 to $30.75.Neutral
2021-03-08 17:28 ESTNewsAnaptysBio fails in mid-stage study for Imsidolimab in skin diseaseN/A
2021-03-08 17:27 ESTNewsAnaptysBio gets double downgrade at JPM after Imsidolimab trial failureN/A
2021-03-03 02:39 ESTNewsAnaptysBio: Upcoming Catalyst Seems Like Quite The GambleN/A
2021-03-01 15:05 ESTAnalyst RatingThe Analyst Target Price has increased from $29.8 to $33.25.Buy
2021-03-01 15:05 ESTEarnings EstimateAn EPS average of -$2.43 is estimated for the 2022 year.Sell
2021-03-01 15:05 ESTEarnings EstimateAn EPS average of -$0.69 is estimated for the quarter ending on June 30, 2021.Sell
2021-02-26 15:05 ESTFinancialsCompany financials have been released.Neutral
2021-02-25 19:20 ESTNewsAnaptysBio EPS beats by $0.15, beats on revenueN/A
2021-02-12 11:05 ESTAnalyst RatingThe Analyst Target Price has increased from $28 to $29.8.Neutral
2021-02-11 20:59 ESTNewsAnaptysBio rises after double-upgrade from JPM; positive risk/reward profile citedN/A
2021-02-11 20:58 ESTNewsAnaptysBio: Troubled History Of Drug DevelopmentN/A
2020-12-13 03:11 ESTFinancialsCompany financials have been released.Neutral
2020-12-01 10:36 ESTNewsAnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% UpsideN/A
2020-11-18 06:57 ESTNewsAnaptysBio (ANAB) Investor Presentation - SlideshowN/A
2020-11-15 11:10 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 11:07 ESTAnalyst RatingThe Analyst Target Price has increased from $27.5 to $28.Neutral

About AnaptysBio, Inc (ANAB):

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

ANAB Quotes by TradingView

See Advanced Chart

General

  • Name AnaptysBio, Inc
  • Symbol ANAB
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 94
  • Fiscal Year EndDecember
  • IPO Date2017-01-26
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.anaptysbio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 8.07
  • Price/Book (Most Recent Quarter) 1.53
  • Enterprise Value Revenue 2.85
  • Enterprise Value EBITDA 0.11
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$3.01
  • Next Year EPS Estimate -$3.09
  • Next Quarter EPS Estimate -$0.61
  • Profit Margin -27%
  • Operating Margin -32%
  • Return on Assets -4%
  • Return on Equity -5%
  • Revenue 75 million
  • Earnings Per Share -$3.01
  • Revenue Per Share $2.75
  • Gross Profit -5025000
  • Quarterly Earnings Growth 1900%
View More

Highlights

  • Market Capitalization 587.28 million
  • EBITDA -87543000
  • PE Ratio -6.14
  • Analyst Target Price $28.5
  • Book Value Per Share $14.50
View More

Share Statistics

  • Shares Outstanding 27.37 million
  • Shares Float 15.89 million
  • % Held by Insiders 77%
  • % Held by Institutions 106.22%
  • Shares Short 3.81 million
  • Shares Short Prior Month 3.74 million
  • Short Ratio 8.99
  • Short % of Float 21%
  • Short % of Shares Outstanding 14%
View More

Technicals

  • Beta 0.13
  • 52 Week High $35.86
  • 52 Week Low $12.46
  • 50 Day Moving Average 26.72
  • 200 Day Moving Average 23.55
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

AnaptysBio, Inc (ANAB) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

AnaptysBio, Inc (ANAB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$60 million$1.20$0.6098.87%
2020-09-302020-11-04$N/A-$0.87-$0.69-26.45%
2020-06-302020-08-10$N/A-$0.79-$0.65-21.18%
2020-03-312020-05-06$N/A-$0.30-$0.8062.5%
2019-12-312020-03-02$3 million-$0.75-$1.2841.36%
2019-09-302019-11-08$N/A-$1.15-$1.14-0.46%
2019-06-302019-08-08$5 million-$0.89-$0.956.66%
2019-03-312019-05-07$N/A-$0.82-$0.78-4.75%
2018-12-312019-02-28$N/A-$0.64-$0.8625.93%
2018-09-302018-11-08$5 million-$0.66-$0.706.16%
2018-06-302018-08-07$N/A-$0.57-$0.6714.41%
2018-03-312018-05-08$N/A-$0.63-$0.46-36.22%
2017-12-312018-03-05$3 million-$0.30-$0.4228.37%
2017-09-302017-11-07$-7000000-$0.45-$0.474.56%
2017-06-302017-08-10$7 million-$0.13-$0.4269.34%
2017-03-312017-05-11$N/A-$0.75-$0.18-310.96%
2016-12-312017-03-08$2.75 million-$0.19-$0.10-86.34%

AnaptysBio, Inc (ANAB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 21.57 million N/A N/A N/A 21.43 million
Income Before Tax 33.65 million N/A N/A N/A -20.29 million
Selling General Administrative 5.09 million N/A N/A N/A 3.83 million
Gross Profit 60 million N/A N/A N/A 3 million
Ebit 36.89 million N/A N/A N/A -22.26 million
Operating Income 33.35 million N/A N/A N/A -22.26 million
Income Tax Expense N/A N/A N/A N/A -22000
Total Revenue 60 million N/A N/A N/A 3 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A 1.97 million
Net Income From Continuing Operations 33.65 million N/A N/A N/A -20.26 million
Net Income Applicable to Common Shares 33.65 million -23.77 million -21.55 million -8.26 million -20.26 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities 4.06 million -3.3 million -5.19 million N/A N/A
Total Cash Flow from Investing Activities 4.73 million 75.39 million 10.75 million N/A N/A
Net Borrowings N/A N/A -1.38 million N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A N/A
Change to Operating Activities -424000 -2.71 million 233000 N/A N/A
Change in Cash N/A N/A N/A N/A N/A
Total Cash from Operating Activities -17.01 million -19.61 million -15.11 million N/A N/A
Depreciation N/A N/A N/A N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 2.98 million 2.81 million 2.97 million N/A N/A
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 19.82 million N/A N/A N/A 30.19 million
Total Stockholder Equity 396.73 million N/A N/A N/A 405.01 million
Other Current Liabilities 342000 851000 N/A N/A 871000
Total Assets 416.55 million N/A N/A N/A 435.2 million
Common Stock 27000 27000 27000 27000 27000
Other Current Assets 2.91 million N/A N/A N/A N/A
Retained Earnings -263.96 million -297.6 million -273.84 million -252.29 million -244.03 million
Other Liabilities N/A 33000 180000 N/A 654000
Other Assets N/A 1.17 million 1.41 million 140000 1.54 million
Cash 250.46 million N/A N/A N/A 171.02 million
Total Current Liabilities 19.82 million 24.47 million N/A N/A 29.54 million
Other Stockholder Equity -4000 259000 753000 1.15 million 338000
Property, Plant & Equipment 1.78 million 1.59 million 1.5 million 2.82 million 1.62 million
Total Current Assets 396.56 million 345.81 million N/A N/A 377.73 million
Long Term Investments 17.55 million N/A N/A N/A 54.31 million
Net Tangible Assets 396.73 million 360.24 million 381.44 million 400.56 million 405.01 million
Short Term Investments 143.2 million N/A N/A N/A 203.21 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 19.48 million 5.48 million N/A N/A 16.24 million

AnaptysBio, Inc (ANAB) Chart:

AnaptysBio, Inc (ANAB) News:

Below you will find a list of latest news for AnaptysBio, Inc (ANAB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

AnaptysBio, Inc (ANAB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-02-2012.520.7CALL0 530TRUE00
2026-02-20150CALL0 00TRUE00
2026-02-2017.520.3CALL0 00TRUE00
2026-02-202028CALL0 00TRUE00
2026-02-2022.517.7CALL0 00TRUE00
2026-02-202524.54CALL0 20TRUE00
2026-02-203013.94CALL0 160TRUE00
2026-02-203512.55CALL0 200TRUE00
2026-02-20407.55CALL0 32107.32TRUE00
2026-02-20456.5CALL5 4019101.53TRUE1.50.3
2026-02-20502.5CALL0 4374.94TRUE00
2026-02-20550.89CALL0 28121.7FALSE00
2026-02-20600.77CALL0 6110.9FALSE00
2026-02-20650CALL0 0284.95FALSE00
2026-02-20700CALL0 0317.02FALSE00
2026-02-2012.50.1PUT0 121135.89FALSE00
2026-02-20153.28PUT0 6981.9FALSE00
2026-02-2017.51.55PUT0 1863.19FALSE00
2026-02-20200PUT0 0766.67FALSE00
2026-02-2022.54.85PUT0 0685.28FALSE00
2026-02-20255.27PUT0 0614.78FALSE00
2026-02-20304.4PUT0 5496.31FALSE00
2026-02-20350.15PUT0 3397.74FALSE00
2026-02-20401.45PUT0 0311.42FALSE00
2026-02-20450.95PUT0 18792.75FALSE00
2026-02-20506.25PUT0 2152.78FALSE00
2026-02-20556.8PUT0 154.89TRUE00
2026-02-20600PUT0 00TRUE00
2026-02-20650PUT0 00TRUE00
2026-02-20700PUT0 00TRUE00
2026-03-20250CALL0 0122.95TRUE00
2026-03-20300CALL0 073.07TRUE00
2026-03-20350CALL0 049.33TRUE00
2026-03-20400CALL0 074.53TRUE00
2026-03-20457CALL0 177.2TRUE00
2026-03-20504.7CALL2 369.73TRUE0.770.2
2026-03-20552.45CALL0 3103.18FALSE00
2026-03-20600CALL0 0126.34FALSE00
2026-03-20650CALL0 0145.52FALSE00
2026-03-20700CALL0 0162.01FALSE00
2026-03-20250PUT0 0316.24FALSE00
2026-03-20300PUT0 0200.21FALSE00
2026-03-20350PUT0 0204.88FALSE00
2026-03-20400PUT0 0160.62FALSE00
2026-03-20452PUT0 3119.85FALSE00
2026-03-20500PUT0 077.86FALSE00
2026-03-20550PUT0 058.37TRUE00
2026-03-20600PUT0 054.38TRUE00
2026-03-20650PUT0 052.49TRUE00
2026-03-20700PUT0 00TRUE00
2026-05-152.50CALL0 00TRUE00
2026-05-1550CALL0 0235.14TRUE00
2026-05-157.50CALL0 0205.55TRUE00
2026-05-15100CALL0 0171.1TRUE00
2026-05-1512.50CALL0 0145.1TRUE00
2026-05-151523.5CALL0 1124.18TRUE00
2026-05-1517.50CALL0 0106.66TRUE00
2026-05-15200CALL0 091.53TRUE00
2026-05-1522.50CALL0 078.15TRUE00
2026-05-15250CALL0 066.05TRUE00
2026-05-153018.28CALL0 5473.95TRUE00
2026-05-153512.75CALL0 973.16TRUE00
2026-05-154010CALL0 668.08TRUE00
2026-05-15456.8CALL0 263.95TRUE00
2026-05-15508.65CALL0 6764.03TRUE00
2026-05-15554.28CALL0 2563.34FALSE00
2026-05-15603.54CALL0 562.76FALSE00
2026-05-15650CALL0 091.7FALSE00
2026-05-15702.21CALL0 1102.23FALSE00
2026-05-15750CALL0 0111.49FALSE00
2026-05-152.50PUT0 00FALSE00
2026-05-1550PUT0 01110.42FALSE00
2026-05-157.50PUT0 0565.4FALSE00
2026-05-15100PUT0 0444.16FALSE00
2026-05-1512.50PUT0 0372.66FALSE00
2026-05-15150PUT0 0249.89FALSE00
2026-05-1517.51.9PUT0 0283.37FALSE00
2026-05-15203.35PUT0 10251.8FALSE00
2026-05-1522.50PUT0 0225.19FALSE00
2026-05-15255.4PUT0 1202.15FALSE00
2026-05-15302.62PUT0 8163.47FALSE00
2026-05-15351.53PUT0 2131.31FALSE00
2026-05-15403PUT0 13103.18FALSE00
2026-05-15456PUT0 864.45FALSE00
2026-05-15508PUT0 259.77FALSE00
2026-05-15550PUT0 059.12TRUE00
2026-05-15600PUT0 058.33TRUE00
2026-05-15650PUT0 059.3TRUE00
2026-05-15700PUT0 056.1TRUE00
2026-05-15750PUT0 053.71TRUE00
2026-08-2122.50CALL0 086.24TRUE00
2026-08-212525.28CALL0 2075.63TRUE00
2026-08-213021.65CALL0 371.74TRUE00
2026-08-213518.03CALL0 173.22TRUE00
2026-08-214014.63CALL0 268.9TRUE00
2026-08-214512.63CALL0 368.86TRUE00
2026-08-215010.02CALL0 4570.02TRUE00
2026-08-21557.38CALL0 263.94FALSE00
2026-08-21605.3CALL0 3464.96FALSE00
2026-08-21650CALL0 064.09FALSE00
2026-08-21700CALL0 068.23FALSE00
2026-08-21750CALL0 068.94FALSE00
2026-08-2122.50PUT0 0158.85FALSE00
2026-08-21250PUT0 0142.7FALSE00
2026-08-21300PUT0 0115.59FALSE00
2026-08-21350PUT0 081.59FALSE00
2026-08-21400PUT0 079.64FALSE00
2026-08-21457.16PUT0 574.12FALSE00
2026-08-21500PUT0 062.06FALSE00
2026-08-21550PUT0 062.18TRUE00
2026-08-21600PUT0 061.05TRUE00
2026-08-21650PUT0 061.14TRUE00
2026-08-21700PUT0 061.09TRUE00
2026-08-21750PUT0 057.6TRUE00

Latest ANAB Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST8$21.35
Jun 13, 2022 7:59 PM EST1$21.35
Jun 13, 2022 7:59 PM EST200$21.35
Jun 13, 2022 7:59 PM EST54$21.35
Jun 13, 2022 7:59 PM EST13$21.35

AnaptysBio, Inc (ANAB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000039/0001370053-20-000039-index.htm
2018-09-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1370053/000000000018028147/0000000000-18-028147-index.htm
2018-10-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1370053/000000000018032332/0000000000-18-032332-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000009375120000338/0000093751-20-000338-index.htm
2019-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000021545719003201/0000215457-19-003201-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000031506619000857/0000315066-19-000857-index.htm
2019-12-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000031506619001800/0000315066-19-001800-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000083423720004777/0000834237-20-004777-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000090266419000927/0000902664-19-000927-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000090266420000965/0000902664-20-000965-index.htm
2020-02-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000092189520000234/0000921895-20-000234-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000092963819000269/0000929638-19-000269-index.htm
2019-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000093247119004736/0000932471-19-004736-index.htm
2019-11-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000093583619000611/0000935836-19-000611-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000093583620000141/0000935836-20-000141-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000101297518000436/0001012975-18-000436-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000101297518000437/0001012975-18-000437-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000101297518000438/0001012975-18-000438-index.htm
2018-05-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1370053/000107261318000346/0001072613-18-000346-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000110465920018330/0001104659-20-018330-index.htm
2018-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518089132/0001193125-18-089132-index.htm
2018-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518095907/0001193125-18-095907-index.htm
2018-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518280420/0001193125-18-280420-index.htm
2018-09-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1370053/000119312518281156/0001193125-18-281156-index.htm
2018-09-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1370053/000119312518283918/0001193125-18-283918-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518283933/0001193125-18-283933-index.htm
2019-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1370053/000119312519041203/0001193125-19-041203-index.htm
2020-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312520225721/0001193125-20-225721-index.htm
2018-03-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118017376/0001209191-18-017376-index.htm
2018-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118017377/0001209191-18-017377-index.htm
2018-04-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118036984/0001209191-18-036984-index.htm
2018-07-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-08-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118045891/0001209191-18-045891-index.htm
2018-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118045892/0001209191-18-045892-index.htm
2018-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118050362/0001209191-18-050362-index.htm
2018-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009006/0001209191-19-009006-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009024/0001209191-19-009024-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009028/0001209191-19-009028-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009031/0001209191-19-009031-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009034/0001209191-19-009034-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009036/0001209191-19-009036-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009038/0001209191-19-009038-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009043/0001209191-19-009043-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009044/0001209191-19-009044-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009046/0001209191-19-009046-index.htm
2019-04-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119025283/0001209191-19-025283-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119046820/0001209191-19-046820-index.htm
2019-09-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119050888/0001209191-19-050888-index.htm
2019-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119050889/0001209191-19-050889-index.htm
2019-11-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119057952/0001209191-19-057952-index.htm
2019-12-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119058549/0001209191-19-058549-index.htm
2019-12-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119059923/0001209191-19-059923-index.htm
2019-12-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119059924/0001209191-19-059924-index.htm
2019-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119060981/0001209191-19-060981-index.htm
2020-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120007246/0001209191-20-007246-index.htm
2020-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120007251/0001209191-20-007251-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009309/0001209191-20-009309-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009316/0001209191-20-009316-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009322/0001209191-20-009322-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009325/0001209191-20-009325-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009327/0001209191-20-009327-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009329/0001209191-20-009329-index.htm
2020-03-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120017742/0001209191-20-017742-index.htm
2020-07-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120042503/0001209191-20-042503-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120042505/0001209191-20-042505-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120042506/0001209191-20-042506-index.htm
2020-07-313Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120044257/0001209191-20-044257-index.htm
2020-07-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120044259/0001209191-20-044259-index.htm
2019-11-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000121465919007372/0001214659-19-007372-index.htm
2018-06-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000127417318000087/0001274173-18-000087-index.htm
2019-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000127417319000033/0001274173-19-000033-index.htm
2019-12-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000127417319000125/0001274173-19-000125-index.htm
2019-08-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000131924419000074/0001319244-19-000074-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000131924420000020/0001319244-20-000020-index.htm
2018-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000020/0001370053-18-000020-index.htm
2018-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000022/0001370053-18-000022-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000026/0001370053-18-000026-index.htm
2018-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000027/0001370053-18-000027-index.htm
2018-05-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000029/0001370053-18-000029-index.htm
2018-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000031/0001370053-18-000031-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000036/0001370053-18-000036-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000037/0001370053-18-000037-index.htm
2018-09-1410-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000041/0001370053-18-000041-index.htm
2018-09-1410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000042/0001370053-18-000042-index.htm
2018-09-1410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000043/0001370053-18-000043-index.htm
2018-09-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000046/0001370053-18-000046-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000051/0001370053-18-000051-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000052/0001370053-18-000052-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000004/0001370053-19-000004-index.htm
2019-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000006/0001370053-19-000006-index.htm
2019-02-28S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000007/0001370053-19-000007-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000013/0001370053-19-000013-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000014/0001370053-19-000014-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000018/0001370053-19-000018-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000019/0001370053-19-000019-index.htm
2019-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000021/0001370053-19-000021-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000026/0001370053-19-000026-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000027/0001370053-19-000027-index.htm
2019-08-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000029/0001370053-19-000029-index.htm
2019-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000031/0001370053-19-000031-index.htm
2019-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000035/0001370053-19-000035-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000041/0001370053-19-000041-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000042/0001370053-19-000042-index.htm
2020-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000003/0001370053-20-000003-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000007/0001370053-20-000007-index.htm
2020-03-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000009/0001370053-20-000009-index.htm
2020-03-02S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000010/0001370053-20-000010-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000013/0001370053-20-000013-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000019/0001370053-20-000019-index.htm
2020-04-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000020/0001370053-20-000020-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000025/0001370053-20-000025-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000026/0001370053-20-000026-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000039/0001370053-20-000039-index.htm
2020-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000042/0001370053-20-000042-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000045/0001370053-20-000045-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000050/0001370053-20-000050-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000051/0001370053-20-000051-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000053/0001370053-20-000053-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000057/0001370053-20-000057-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000064/0001370053-20-000064-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000065/0001370053-20-000065-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000162363220000230/0001623632-20-000230-index.htm
2020-04-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000162363220000855/0001623632-20-000855-index.htm

AnaptysBio, Inc (ANAB) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of AnaptysBio, Inc (ANAB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 77%
Institutional Ownership: 10622%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-12-03Dominic PiscitelliChief Financial OfficerSell1,100.0075.8183,390.010.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell4,820.0072.24348,212.2210,022.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell6,624.0074.33492,361.921,100.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-09-07Marco LondeiChief Medical OfficerBuy142,857.000.7099,999.90144,877.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118050362/0001209191-18-050362-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell6,741.0068.47461,577.84144,877.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell18,604.0071.331,327,060.5314,842.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell8,002.0067.57540,683.94151,618.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerBuy8,048.000.705,633.60152,925.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell3,185.0066.38211,416.16159,620.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell12,120.0065.36792,177.74162,805.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerBuy22,000.006.93152,460.00174,925.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2019-06-10Hamza SuriaPresident, CEOSell454.0076.3134,644.7417,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-10Hamza SuriaPresident, CEOSell1,994.0075.86151,270.8218,090.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-10Hamza SuriaPresident, CEOSell5,000.0074.68373,412.5020,084.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-01-15Marco LondeiChief Medical OfficerSell14,894.0070.041,043,195.1222,377.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-06-04Marco LondeiChief Medical OfficerSell2,003.0074.50149,219.0922,377.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-04Marco LondeiChief Medical OfficerSell2,048.0073.43150,383.8224,380.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-10Hamza SuriaPresident, CEOSell6,440.0073.70474,637.0225,084.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-04Marco LondeiChief Medical OfficerSell6,009.0072.45435,358.6626,428.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2018-04-16Nicholas LydonDirectorSell2,222.0090.26200,549.05271,106.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-04-16Nicholas LydonDirectorSell2,803.0089.42250,631.37273,328.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-06-08Hamza SuriaPresident, CEOBuy22,428.002.5958,088.5227,426.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118036984/0001209191-18-036984-index.htm
2018-04-16Nicholas LydonDirectorSell4,250.0088.30375,267.35276,131.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2019-11-22Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0027,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119057952/0001209191-19-057952-index.htm
2018-04-16Nicholas LydonDirectorSell9,425.0087.46824,340.66280,381.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-07-09Hamza SuriaPresident, CEOBuy1,428.002.243,198.7228,854.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-04-16Nicholas LydonDirectorSell1,390.0086.15119,752.95289,806.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-04-16Nicholas LydonDirectorSell10,310.0085.11877,491.32291,196.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-12-11Hamza SuriaPresident, CEOSell4,998.0070.83354,008.3430,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-12Hamza SuriaPresident, CEOSell8,324.0072.88606,618.1630,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-14Hamza SuriaPresident, CEOSell7,800.0070.51549,978.7830,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2019-01-14Hamza SuriaPresident, CEOSell12,240.0071.10870,304.3930,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-04-16Nicholas LydonDirectorSell2,600.0084.18218,879.96301,506.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2019-06-10Hamza SuriaPresident, CEOSell8,540.0072.64620,384.8831,524.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-04Marco LondeiChief Medical OfficerBuy10,060.000.707,042.0032,437.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell3,554.0070.34249,974.1433,446.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-07-09Hamza SuriaPresident, CEOBuy6,208.001.619,994.8835,062.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-12-10Hamza SuriaPresident, CEOSell4,964.0072.48359,805.1235,062.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-12-10J. Anthony WareDirectorBuy3,600.0014.0550,580.003,600.00https://www.sec.gov/Archives/edgar/data/1370053/000120919120007251/0001209191-20-007251-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerBuy37,000.0011.34419,580.0037,000.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2019-01-15Marco LondeiChief Medical OfficerSell4,181.0069.29289,686.4437,271.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2020-02-05Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0037,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919120007246/0001209191-20-007246-index.htm
2018-12-14Hamza SuriaPresident, CEOSell9,084.0069.68632,967.6737,864.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-12Hamza SuriaPresident, CEOSell9,673.0071.92695,717.9538,388.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10Hamza SuriaPresident, CEOSell10,347.0071.49739,700.8240,026.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-04-17Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0040,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119025283/0001209191-19-025283-index.htm
2019-01-15Marco LondeiChief Medical OfficerBuy19,075.006.93132,189.7541,452.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-01-14Hamza SuriaPresident, CEOSell27,760.0070.651,961,227.3442,304.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-12-14Hamza SuriaPresident, CEOSell24,844.0068.891,711,428.6346,948.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2020-03-10Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0047,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919120017742/0001209191-20-017742-index.htm
2018-12-12Hamza SuriaPresident, CEOSell12,003.0071.11853,480.5248,061.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10Hamza SuriaPresident, CEOSell15,276.0070.571,078,082.3150,373.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-12Hamza SuriaPresident, CEOBuy30,000.001.1233,600.0060,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10Hamza SuriaPresident, CEOBuy30,587.001.1234,257.4465,649.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-11-27Marco LondeiChief Medical OfficerBuy46,202.006.93320,179.8668,579.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119058549/0001209191-19-058549-index.htm
2019-01-14Hamza SuriaPresident, CEOBuy40,000.001.1244,800.0070,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-12-14Hamza SuriaPresident, CEOBuy41,728.001.1246,735.3671,792.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell2,298.0073.18168,158.687,724.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm